Based on the Belite Bio Inc ADR stock forecast from 2 analysts, the average analyst target price for Belite Bio Inc ADR is USD 58.67 over the next 12 months. Belite Bio Inc ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Belite Bio Inc ADR is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Belite Bio Inc ADR’s stock price was USD 64.98. Belite Bio Inc ADR’s stock price has changed by +16.08% over the past week, +34.76% over the past month and +77.64% over the last year.
No recent analyst target price found for Belite Bio Inc ADR
No recent average analyst rating found for Belite Bio Inc ADR
Company Overview Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. Read Less
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (...Read More
Frequently Asked Questions About Belite Bio Inc ADR (BLTE) Stock
Based on ratings from 2 analysts Belite Bio Inc ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLTE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for BLTE is USD 58.67 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 57.
Unfortunately we do not have enough data on BLTE's stock to indicate if its overvalued.
The last closing price of BLTE's stock was USD 64.98.
The most recent market capitalization for BLTE is USD 1.71B.
Based on targets from 2 analysts, the average taret price for BLTE is projected at USD 58.67 over the next 12 months.
This means that BLTE's stock price may go down by -9.72% over the next 12 months.
We can't find any ETFs which contains Belite Bio Inc ADR's stock.
As per our most recent records Belite Bio Inc ADR has 20 Employees.
Belite Bio Inc ADR's registered address is 12750 High Bluff Drive, San Diego, CA, United States, 92130.
You can get more information about it from Belite Bio Inc ADR's website at https://www.belitebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Belite Bio Inc ADR (BLTE) Stock
Based on ratings from 2 analysts Belite Bio Inc ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLTE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for BLTE is USD 58.67 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 57.
Unfortunately we do not have enough data on BLTE's stock to indicate if its overvalued.
The last closing price of BLTE's stock was USD 64.98.
The most recent market capitalization for BLTE is USD 1.71B.
Based on targets from 2 analysts, the average taret price for BLTE is projected at USD 58.67 over the next 12 months.
This means that BLTE's stock price may go down by -9.72% over the next 12 months.
We can't find any ETFs which contains Belite Bio Inc ADR's stock.
As per our most recent records Belite Bio Inc ADR has 20 Employees.
Belite Bio Inc ADR's registered address is 12750 High Bluff Drive, San Diego, CA, United States, 92130.
You can get more information about it from Belite Bio Inc ADR's website at https://www.belitebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLTE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
